Peger Biopharmaceutical-B (02565): The first batch of commercialized prescriptions of Patacom® was launched in the country and the second equity payment terms were reached

^{According to the Zhitong Finance App, Peger Biopharmaceutical-B (02565) announced that as of July 22, 2026, Pidacang® has successively issued the first batch of commercialized prescriptions in the country at various medical institutions, including Peking University People's Hospital and the Second Xiangya Hospital of Central South University. Among the representative medical institutions mentioned above, the first prescription from Peking University People's Hospital was prescribed by Professor Ji Linong, one of the leading experts in the Pai Dakang® Phase III clinical study and director of the Department of Endocrinology; Professor Zhou Zhiguang, one of the leading experts in the Phase III clinical research of Central South University and a leader in the national key discipline of metabolic endocrinology, was prescribed by Professor Ji Linong, one of the leading experts in the Phase III clinical study of Pai Da Kang® and the head of the Department of Endocrinology.}

^{The successful implementation of the first batch of commercial prescriptions in the country marks the official entry of Pidacan® into clinical application and patient use. It also marks the completion of an important leap from independent research, clinical research and approval for marketing to commercial application of the first innovative drug independently developed by the Group.}

Patacang ^® is a long-term glucagon-like peptide-1 receptor agonist (GLP-1RA) weekly formulation independently developed by the Group. It has been approved by the China National Drug Administration for the treatment of type 2 diabetes in adults. Paidacan® is administered once a week with a fixed therapeutic dose of 0.97 mg. The initial dose does not require dose titration, and has shown continuous and stable blood sugar control ability, good safety and gastrointestinal tolerance, and multiple metabolic benefits in clinical studies.

^{According to the commercialization cooperation agreement between the Group and Tengrui Pharmaceuticals, with the successful issuance of the first batch of commercial prescriptions of Pidacom® in the country, the second equity payment terms agreed in the agreement have all been fulfilled, and Tengrui Pharmaceuticals's obligation to pay this benefit has officially come into effect.} Tengrui Pharmaceutical has confirmed in writing that the above payment terms have been met, and will pay the second installment of the equity amount of approximately HK$49 million as agreed in the commercial cooperation agreement. The Group expects to receive this amount within the payment period agreed in the commercial cooperation agreement.

The board of directors believes that the launch of the first batch of commercialized prescriptions of Pidacang ^® in the country is an important milestone in the formal entry of the product into clinical application and patient service; the achievement of the second equity payment terms also further reflects the substantial progress and continuous implementation of the commercial cooperation between the Group and Tengrui Pharmaceuticals. ^{These developments mark significant progress in both clinical application and commercialization cooperation of Patacom®.}

^{The Group will continue to work closely with Tengrui Pharmaceuticals to promote market access, academic promotion, channel construction, terminal coverage and patient services in mainland China, and continue to improve product quality management and stable supply to further enhance the clinical and patient accessibility of Paidacang ®.}